CURRICULUM VITAE

Rajiv R. Rathod, M.D., M.B.A.

Fellow, American Academy of Ophthalmology

CA Medical License #A120894

Mailing/Contact Address:
Orange County Retina Medical Group
1200 North Tustin Avenue, Suite 140
Santa Ana, California 92705
714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Orange County Retina Medical Group
Physician/Surgeon/Partner/Clinical Trial Investigator
Since July 2012

Locations

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

EDUCATION AND TRAINING

Vitreo-Retinal Fellowship
University of Illinois
Chicago, Illinois; 2010-2012

Residency
Chief Resident, Ophthalmology
Washington University School of Medicine
St. Louis, Missouri; 2009-2010

Ophthalmology
Washington University School of Medicine / Barnes-Jewish Hospital
St. Louis, Missouri; 2006-2009

Internship in Medicine
Santa Clara Valley Medical Center Transitional Internship
Stanford University School of Medicine
San Jose, California; 2005-2006

Medical School
Medical Doctorate
Vanderbilt University School of Medicine
Nashville, Tennessee; 2000-2005

Graduate
Master of Business Administration
Owen Graduate School of Management
Vanderbilt University
Nashville, Tennessee; 2003-2005

Undergraduate
Bachelor of Science, Biological Sciences
Stanford University
Stanford, California; 1995-1999

BOARD CERTIFICATION

American Board of Ophthalmology, Diplomate 2012
United States Medical Licensing Examination, Diplomate 2006

MEDICAL LICENSURE

California, issued 2012
Illinois, through 7/31/14
Missouri, through 1/31/11

HONORS

2011 Fellow of the Year Award, University of Illinois at Chicago
2010 "Golden Apple" Best Teacher Award, Washington University
2009 Mat Guirgis Pediatric Ophthalmology & Strabismus Award: Outstanding Resident, Washington University
2009 Ron Burde Award (dedication to teaching and patient care), Washington University
2008 Career Physician Chief Resident Program Competition Winner
2005 Beta Gamma Sigma, Vanderbilt Chapter
2004 Tulane Business Plan Competition, Second Place
2001 Microbes and Defense Society, Vanderbilt University
2001 Top Spear Award (top student in physiology course), Vanderbilt University

PROFESSIONAL ORGANIZATIONS

American Academy of Ophthalmology
American Medical Association
Chicago Ophthalmological Society
Club Vit
Missouri Society of Eye Physicians and Surgeons
St. Louis Ophthalmological Society

HOSPITAL/SURGERY CENTER AFFILIATIONS

08/2012 – Present	Barranca Surgery Center, Irvine, California
08/2012 – Present	Orange County Global Medical Center (formerly Western Medical Center), Santa Ana, California
08/2012 – Present	Pacifica Hills Surgery Center, Laguna Hills, California
08/2012 – Present	St. Jude Medical Center, Fullerton, California
10/2012 – Present	Anaheim Regional Medical Center, Anaheim, California
10/2012 – Present	Children's Hospital at Mission, Mission Viejo, California
10/2012 – Present	Children's Hospital of Orange County, Orange, California
10/2012 – Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
11/2012 – Present	St. Joseph Hospital, Orange, California
12/2015 – Present	LaVeta Surgical Center, Irvine, California
04/2016 – Present	Saddleback Memorial Medical Center

CLINICAL RESEARCH

Six years of experience, prior to July 2012, in conducting research in ophthalmology-related topics including endophthalmitis, vitreoretinal surgery, retinal detachment repair, and sickle cell retinopathy.

01. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA; 2012-2015
    Sub-Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation Isonep™ (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to AMD*

02. Alimera Sciences, Protocol C-01-11-008 (FAME) Extension Study; 2012-2013
    Sub-Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME*

03. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III; 2012-2013
    Sub-Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*

04. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II; 2012-2013
    Sub-Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*

05. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD™ -A), Phase III; 2012-2015
    Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*

06. Pfizer, Protocol B1181003-1050 (DREAM), Phase II; 2012-2013
    Sub-Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*

07. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III, 2012-2015
    Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*

08. Regeneron, Protocol VGFTe-AMD-1124 (RE-VIEW), Phase IV; 2012-2015
    Sub-Investigator. *Rigorous evaluation of vision and safety with intravitreal afliberecept injection dosed every 8 weeks over 2 years in neovascular AMD*

09. Merck, Protocol MK8931—017 (SCH 900931, P07738) (EPOCH), Phase 2/3, Collaborative Study; 2012-Present
    Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*

10. Allergan, Protocol GMA-OZU-13-598 (ECHO), Retrospective Registry; 2013-2014
    Sub-Investigator. *A retrospective data collection study in patients receiving anti-VEGF injections for retinal vein occlusion or diabetic macular edema*

11. Opththotech, Protocol OPH1003 (ECLIPSE), Phase III; 2013-2017
Sub-Investigator. *A double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

12. Aerpio, Protocol AKB-9778-CI-2003 (TIME 2), Phase II; 2014-2015
Principal Investigator. *A phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with diabetic macular edema*

13. Xoma, Protocol X052132 (EYEGUARD™ -E), Phase III; 2014-2016
Sub-Investigator. *An open-label, non-randomized, single-arm, roll-over study to continue dosing of Gevokizumab in non-infectious intermediate, posterior, or pan-uveitis patients who each successfully completed either the X052130 or the X052131 study*

14. Merck, Protocol MK8931-019 (APECS), Phase III, Collaborative Study; 2014-2018
Ophthalmology Investigator. *A phase III, randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK8931 (SCH900931) in subjects with amnestic mild cognitive impairment due to Alzheimer's Disease (Prodromal AD)*

15. National Eye Institute, SCORE2, Phase III; 2014-2016
Sub-Investigator. *A multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal afliberecept every 4 weeks*

16. Allergan, Protocol #150998-004 (PALM), Phase II; 2014-2015
Principal Investigator. *Evaluation of abicipar pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema*

17. Thrombogenics, Protocol #TG-MV-018 (ORBIT), Prospective Registry, Phase IV; 2014-2016
Sub-Investigator. *Ocriplasmin Research to Better Inform Treatment*

18. Thrombogenics, Protocol #TG-MV-022 (OZONE), Retrospective Registry, Phase IV, 2014-2015
Sub-Investigator. *Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study*

19. Allergan, Protocol #GMA-US-EYE-0272 (REINFORCE), Prospective Registry, Phase IV; 2014-2016
Sub-Investigator. *The Ozurdex Diabetic Macular Edema Patient Registry*

20. Hoffmann-La Roche, Protocol #GX29176 (CHROMA), Phase III; 2014-2018
Sub-Investigator. *A randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration*

21. Xoma, Protocol X052133 (EYEGUARD™ -US), Phase III; 2015-2015
Sub-Investigator. *A randomized-withdrawal, double-masked, placebo-controlled study of the efficacy and safety of gevokizumab in treating subjects with Behçet's disease uveitis*

22. Allegro Ophthalmics, Protocol DME-202B (DEL MAR), Phase II; 2015-2015
Sub-Investigator. *A phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminate® (ALG-1001) as compared to Avastin® and focal laser photocoagulation in the treatment of diabetic macular edema*

23. Iconic Therapeutics, Protocol IT-002 (EMERGE), Phase II; 2015-2016
Sub-Investigator. *A phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1™ in patients with choroidal neovascularization secondary to age-related macular degeneration*

24. Bayer, Protocol BAY 73-4506/15984 (DREAM), Phase IIa/IIB; 2015-2015
Sub-Investigator. *A combined phase IIa/IIb study of the efficacy, safety and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration*

25. Allergan, Protocol 150998-005 (CEDAR), Phase III; 2015-Present
Sub-Investigator. *A multicenter, randomized, double-masked, parallel-group, active-controlled study evaluating the safety and efficacy of abicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration*

26. Ophthotech, Protocol OPH1004, Phase III; 2015-2016
Sub-Investigator. *A phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (anit PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

27. Ophthotech, Protocol OPH1005 Phase III; 2015-2016
Sub-Investigator. *A 24 month, phase 2a, open label, safety study of Fovista (anti-PDGF-BB pegylated aptamer) regimen administered in combination with anti-VEGF therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy*

28. Ophthotech, Protocol OPH1006 Phase III; 2015-2017
Sub-Investigator. *Effect of anti-VEGF agents administered on a quarterly maintenance regimen in subjects with neovascular AMD receiving anti-PDGF therapy: An 18-month, phase 2a, open-label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)*

29. Regeneron, Protocol R2176-3-AMD-1417 (CAPELLA), Phase II; 2015-2017
Sub-Investigator. *A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration*

30. Astellas, Protocol 8232-CL-3001 (VIDI), Phase III; 2015-2016
Principal Investigator. *A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema*

31. Alcon, Protocol RTH258-C001 (HAWK), Phase III; 2015-2018
Sub-Investigator. *A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration*

32. Clearside Biomedical Protocol #CLS1001-301 (PEACHTREE), Phase III; 2015-2018
Sub-Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*

33. Genentech/Roche, Protocol #GX28228 (LADDER), Phase II; 2016-Present
Sub-Investigator. *A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular AMD*

34. Alimera, Protocol #M-01-15-004 (PALADIN), Phase IV; 2016-Present
Principal Investigator. *A phase IV safety study of IOP signals in patients treated with Iluvien (fluocinolone acetonide intravitreal implant) 0.19mg*

35. Arctic Diagnostics, Protocol #AMD SCI-GEN, Observational Registry, 2016-2018
Site Investigator. *AMD study of the clinical impact of genetics*

36. Eyegate #EGP-437-006, Phase III; 2016-2018
Sub-Investigator. *A prospective, multicenter, randomized, double-masked, positive-controlled, phase 3 clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*

37. ThromboGenics, Protocol #TG-MV-015 (CIRCLE), Phase II; 2016-Present
Sub-Investigator. *phase 2, randomized, double-masked, sham-controlled, multi-centre study to evaluate the efficacy and safety of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy (NPDR)*

38. L. Hoffmann-La Roche, Protocol #BP29647 (AVENUE), Phase II; 2016-2018
Sub-Investigator. *A multiple-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36 week study to investigator the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with choroidal neovascularization secondary to age-related macular degeneration*

39. L. Hoffmann-La Roche, Protocol #BP30099 (BOULEVARD), Phase II; 2016-2017
Prinicipal Investigator. *A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with diabetic macular edema*

40. Actelion, Protocol #ACT-058B301 (OPTIMUM), Phase III Collaborative Trial; 2016-Present
Sub-Investigator. *Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis*

41. Eli Lilly, Protocol #I7X-MC-LLCF (NAVIGATE-AD), Phase II Collaborative Trial; 2016-2018
Ophthalmology Investigator. *Effect of LY3202626 on alzheimer's disease progression as measured by cerebral 18 F-AV-1451 Tau-PET in mild alzheimer's disease dementia*

42. Clearside, Protocol #CLS1001-303 (MAGNOLIA), Phase III; 2017-2018
Sub-Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*

43. Genentech/Roche, Protocol #GX30191 (OMASPECT), Phase IIIb; 2017-2018
Sub-Investigator. *A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a Roche-sponsored study*

44. Clearside, Protocol #CLS1003-301 (SAPPHIRE), Phase III; 2017-2019
Sub-Investigator. *A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal afliberecept in subjects with retinal vein occlusion*

45. Regenerative Patch Technologies, Protocol #RPT-14-001, Phase I; 2017-Present
Sub- Investigator. *A phase I/IIA safety study of subretinal implantation of CPCB-RPE1 (human embryonic stem cell-derived retinal pigment epithelial (RPE) cells seeded on a polymeric substrate) in subjects with advanced, dry age-related macular degeneration (AMD)*

46. VisionCare, Protocol #IMT-TES-2016, Phase IV; 2017-Present
Principal Investigator. *A prospective, multicenter clinical trial of the implantable miniature telescope in pseudophakic eyes with central vision impairment associated with end-stage macular degeneration. TES Study: Telescope Exchange Study*

47. Regeneron, Protocol #VGFTe-OD-1411 "PANORAMA", Phase III; 2017-2018
Sub-Investigator. *A phase 3, double-masked , randomized study of the efficacy and safety of intravitreal afliberecept injection in patients with moderately severe to sever non-proliferative diabetic retinopathy*

48. Allergan, Protocol #VOLUMA-007 "VOLUMA" Collaborative Study, Phase IV; 2017-2017
Ophthalmology Investigator. *A multicenter, single-blind, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel for correction of temple hollowing*

49. Aldeyra, Protocol #ADX-102-UV-005, Phase III; 2017-Present
Sub-Investigator. A phase 3 randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in subjects with non-infectious anterior uveitis

50. Ophthotech, Protocol #OPH2007, Phase II; 2017-2019
Sub-Investigator. A phase 2A open-label trial to assess the safety of Zimura™ (anti-C5) administered in combination with Lucentis® 0.5mg in treatment naïve subjects with neovascular age-related macular degeneration

51. Opthea, Protocol #OPT-302-1002, Phase III; 2017-Present
Sub-Investigator: *A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)*

51. Ophthotech, Protocol #OPH2003, Phase II/III; 2017-Present
Sub-Investigator: *A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura™ (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration*

52. Opthea #OPT 302-1003, Phase IB/IIA; 2017-Present
Principal Investigator: *Phase 1b/2a study of OPT-302 in combination with afliberecept for persistent central-involved diabetic macular edema*

53. Genentech, Protocol GX28228 "LADDER" Sub-Study (OAT), Phase II; 2017-Present
Sub-Investigator. Oral antithrombotic therapy substudy in association with study GX28228: *A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the Ranibizumab Port Delivery System for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration*

54. KalVista, Protocol KVD001-2001, Phase II; 2018-Present
Principal Investigator. *A randomized, sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kalikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment*

55. Iconic, Protocol IT-004 (DECO), Phase II; 2018-Present
Sub-Investigator: *A phase 2 randomized, open-label, multicenter study evaluating administration of repeated intravitreal doses of ICON-1 in patients with choroidal neovascularization secondary to age-related macular degeneration*

56. Eli-Lilly, Protocol #I5T-MC-AACG (TRAILBLAZER), Phase III, Collaborate Study; 2018-Present
Ophthalmology Investigator. *Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination With LY3202626 in Early Symptomatic Alzheimer's Disease*

57. Genentech/Roche, Protocol #GR40349 (YOSEMITE), Phase III; 2018-Present
Principal Investigator. *A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the simultaneous blockade of antiopoietin-2 and VEGF-A with the bispecific antibody RO6867461 (RG7716) in diabetic retinopathy patients with diabetic macular edema*

58. Genentech/Roche, Protocol #GR40549 (PORTAL), Phase III; 2018-Present
Sub-Investigator. *A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration*

59. Genentech/Roche, Protocol #GR40548 (ARCHWAY), Phase III; 2018-Present
Sub-Investigator. *A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration*

60. Apellis, Protocol #APL2-304 (OAKS), Phase III; 2018-Present
Sub-Investigator. *A phase III, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)*

60. Genentech, Protocol #GR40844 (LUCERNE), Phase III; 2019-Present
Principal Investigator. *A phase III, multicenter, randomized, double-masked, active comparator, controlled study to evaluate the efficacy and safety of farcimab in patients with neovascular age-related macular degeneration*

BIBLIOGRAPHY

ARTICLES

01. **Rathod RR**, Mieler WF. An update on the management of intraocular foreign bodies. *Retinal Physician*; April 2011.

PUBLISHED ABSTRACTS/POSTER PRESENTATIONS

01. **Rathod RR**, Shen DJ, Wang MX. Relationship between stromal ablation depth and hyperopic shift after 6 mm phototherapeutic keratectomy using VISX Star Excimer Laser. *Investigative Ophthalmology and Visual Science* 2002;43:E-Abstract 159.

02. **Rathod RR**, Wang MX, Cohen I. Effects of posterior corneal refractive power change on LASIK; June 2002. American Society of Cataract and Refractive Surgery

03. **Rathod RR**, Khanifar A, Kammer JA. Incidence of glaucoma after repeat penetrating keratoplasty. *Investigative Ophthalmology and Visual Science* 2005;46: E-Abstract 130.

04. **Rathod RR**, Apte RS, Blinder KJ. Safety and outcomes of 25-gauge transconjunctival vitreoretinal surgery. *Investigative Ophthalmology and Visual Science* 2008;49: E-Abstract 6002.

05. **Rathod RR**, Rao PK. Incidence of intraocular infection in the setting of systemic fungal infection. *Investigative Ophthalmology and Visual Science* 2009;50: E-Abstract 3554.

06. **Rathod RR**, Lim JI. Outcomes of retinal detachment repair with relaxing retinectomies in cases of severe proliferative vitreoretinopathy. *Investigative Ophthalmology and Visual Science* 2011;52: E-Abstract 6170.

07. **Rathod RR**, Lim JI. The utility of relaxing retinectomies in repair of recurrent retinal detachments with severe proliferative vitreoretinopathy. Presented as poster at American Society of Retina Specialists Meeting; August 2011.

08. You TT, Huang CX, Chen S, Maggiano JM, **Rathod RR**, Chang E, Casiano ME. Extreme patient positioning for retinal surgery in advanced kyphosis. Submitted Aug2014 to *Retinal Cases & Brief Reports*.

PRESENTATIONS

01. *The Role of Submacular Surgery in the Treatment of Choroidal Neovascular Membranes in* POHS
Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; January 31, 2007

02. *Posterior Reversible Encephalopathy Syndrome*
Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; February 21, 2007

03. *Functional Visual Loss*
Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; March 27, 2007

04. *Phase I/II Data*
Eyegate Protocol EGP-437-004. Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis*:,* Anaheim, California; October 3, 2012

05. *Retina Updates: Case Presentations*
Retina Care Symposium, Costa Mesa, California; December 5, 2013

06. *Complications of Cataract Surgery*
South Coast Eye Care Center, Laguna Hills, California; March 14, 2014

07. *Updates on AMD*
JCAHPO Regional Meeting, Costa Mesa, California; March 15, 2014

08. *Maternally Inherited Diabetes and Deafness*
Retina Clinical Exchange for Orange County Ophthalmologists, Newport Beach, California; March 20, 2014

09. *Plaquenil Screening*
Retina Care for Rheumatologists, Santa Ana, California; June 4, 2014

10. *Plaquenil Screening*
NVISION Annual Summer Symposium Program, Anaheim, California; June 22, 2014

11. *Diabetic Macular Edema: Case Studies*
Multidisciplinary Approach for Management of Patients with Diabetic Macular Edema, Irvine, California; September 10, 2014

12. *Retina Case Studies*
Implantable Miniature Telescope and Interesting Retina Cases, Costa Mesa, California; October 1, 2014

13. *Phase II Results*
Allergan CEDAR Study. Beyond Anti-VEGF: New Drug Molecule for Wet AMD, Costa Mesa, California; September 30, 2015

14. *Phase II Results*
Roche/Genentech CHROMA Study. Potential New Treatment for Dry Age-related Macular Degeneration, Newport Beach, California; October 29, 2015

15. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016

16. *Beyond Anti-VEGF: New Drug Molecule for Wet AMD*
Allergan Protocol #150998-005 "CEDAR" Study. Costa Mesa, California; July 21, 2016

17. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016

18. *Surgically Implanted Ranibizumab Reservoir fro Wet AMD*
Genentech/Roche Protocol #GX28228 "LADDER" Study. Anaheim, California; August 24, 2016

19. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016

20. *New Treatment Paradigm? Iontophoretic Dexamethasone for Anterior Uveitis*
Eyegate Protocol #EGP-437-006 Study. Newport Beach, California; October 6, 2016

21. *A Multidisciplinary Approach to Management of Diabetic Eye Disease*
Allergan Clinical Exchange Program. Costa Mesa, California; November 17, 2016

22. *New Treatment Paradigm Series: Stem Cell Patch for Severe Vision Loss*
Regenerative Patch Technologies Protocol #RPT-14-01. Newport Beach, California; June 1, 2017

23. *New Treatment Paradigm Series: Suprachoroidal Therapy for Retinal Vein Occlusion*
Clearside Biomedical Protocol #CLS1003-301, Newport Beach, California; August 30, 2017

24. *New Treatment Paradigm Series: Novel Therapy for Non-Infectious Uveitis*
Aldeyra Therapeutics Protocol #ADX-102-UV-005, Newport Beach, California; March 21, 2018

25. *New Treatment Paradigm Series: Novel Biologic Therapy for Wet AMD*
Iconic Therapeutics Protocol #IT-004, Newport Beach, California; August 29, 2018

26. *New Treatment Paradigm Series: Novel Therapy for Non-Infectious Anterior Uveitis*
Aldeyra Therapeutics Protocol #ADX-102-UV-005, Newport Beach, California; February 12, 2019

27. *New Treatment Paradigm Series: Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Genentech Protocol #GR40548 "ARCHWAY", Newport Beach, California; February 26, 2019

28. *New Treatment Paradigm Series: Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Genentech Protocol #GR40548 "ARCHWAY", Newport Coast, California; February 28, 2019

29. *New Treatment Paradigm Series: New Molecule for the Treatment of DME*
Genentech Protocol #GR40349 "YOSEMITE", Irvine, California; March 7, 2019

COMMUNITY INVOLVEMENT

Mobile Eye Care Clinic for the Homeless, Illumination Foundation, Santa Ana Amory, Santa Ana, California; January 18, 2014

Mobile Eye Care Clinic for the Homeless, Illumination Foundation, Saddleback Memorial Care Hospital, San Clemente, California; November 4, 2012

LANGUAGES

Medical Spanish, Gujarati